Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$0.35 - $1.07 $425,424 - $1.3 Million
1,215,498 Added 63.77%
3,121,689 $1.09 Million
Q4 2023

Feb 14, 2024

SELL
$0.56 - $0.8 $226,000 - $322,858
-403,573 Reduced 17.47%
1,906,191 $1.26 Million
Q4 2022

Feb 14, 2023

SELL
$0.89 - $28.0 $49,217 - $1.55 Million
-55,300 Reduced 2.34%
2,309,764 $2.19 Million
Q3 2021

Nov 15, 2021

BUY
$14.57 - $17.72 $2.91 Million - $3.54 Million
200,000 Added 9.24%
2,365,064 $36.7 Million
Q4 2020

Feb 12, 2021

BUY
$13.2 - $32.74 $28.6 Million - $70.9 Million
2,165,064 New
2,165,064 $59.9 Million

Others Institutions Holding ALGS

About Aligos Therapeutics, Inc.


  • Ticker ALGS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,717,000
  • Market Cap $751M
  • Description
  • Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...
More about ALGS
Track This Portfolio

Track Hhlr Advisors, Ltd. Portfolio

Follow Hhlr Advisors, Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hhlr Advisors, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Hhlr Advisors, Ltd. with notifications on news.